Chimeric Therapeutics (ASX:CHM) Announces $6.6 Million Placement to Advance Clinical Trials
Chimeric Therapeutics (ASX:CHM) announces a $6.6 million placement to fund key clinical trials in its cell therapy pipeline.
Category: ASX-CHM
Chimeric Therapeutics Limited
Chimeric Therapeutics (ASX:CHM) Reports Positive ADVENT-AML Trial Results
Chimeric Therapeutics (ASX:CHM) reports that two of three patients achieved complete response in its ADVENT-AML Phase 1B clinical trial.
Chimeric Therapeutics Limited (ASX:CHM) Announces $3.2 Million Entitlement Offer
Chimeric Therapeutics Limited (ASX:CHM) announces a $3.2 million entitlement offer to fund its ongoing cell therapy clinical trials.